Abstract: Provided herein are methods for treating or preventing, or ameliorating at least one symptom of, a neurodegenerative disease associated with TDP-43 pathology, comprising administering to a subject an effective amount of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO:1 or a conservative variant thereof, optionally linked to a protein destabilization domain sequence, or a nucleic acid molecule encoding said peptide. Also provided is a peptide comprising or consisting of the amino acid sequence of SEQ ID NO:1 or a conservative variant thereof, a chimeric molecule comprising said peptide linked to a protein destabilization domain sequence, and a polynucleotide encoding said peptide or chimeric molecule.

Abstract: The present invention relates to a method of treating a tauopathy in a subject, a method of improving cognitive ability in a subject suffering from cognitive impairment associated with a tauopathy, a method of reducing tau aggregates and neurofibrillary tangles. The method comprises administering an agent which promotes phosphorylation of tau at threonine in the sequence SSPGSPGTPGSRSR of the tau; and/or introduces a phosphomimetic of a phosphorylated tau, wherein the phosphorylated tau is tau that has been phosphorylated at threonine in the sequence SSPGSPGTPGSRSR of the tau.

Abstract: Disclosed herein are methods for treating or preventing an excitotoxicity-related condition, optionally a condition associated with seizures and/or resulting from or associated with a cerebral ischemic event, comprising administering to a subject in need an effective amount of an inhibitor of Lim-domain kinase 1 (LIMK1). Also provided are methods for treating or preventing seizures and for reducing excitotoxicity in neurons and/or protecting neurons from excitotoxicity.

Abstract: Provided herein are methods for treating, delaying the onset of, or ameliorating at least one symptom of, dementia associated with #-amyloid (A#) accumulation, and for improving memory in subjects suffering from dementia associated with A# accumulation, comprising administering to subjects in need thereof an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for reducing A# toxicity in neurons, comprising exposing neurons to an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof.